Top Players and Competitive Overview in the Lisinopril Market

The lisinopril market is poised for substantial expansion in the coming years, driven by multiple healthcare trends and increasing demand for effective cardiovascular treatments. Understanding the current market size, major players, evolving trends, and key segments helps provide a clearer picture of where this industry is heading.

Growth Forecast and Market Size of the Lisinopril Industry
The lisinopril market is projected to reach a valuation of $2.47 billion by 2030, growing steadily at a compound annual growth rate (CAGR) of 5.5%. Several factors support this anticipated growth, including a rising prevalence of cardiovascular diseases, a growing preference for affordable generic medications, heightened emphasis on preventive cardiac care, expanded use of lisinopril in managing diabetic kidney disease, and increased healthcare expenditure on chronic disease management. Key market trends during this period include a higher incidence of hypertension and cardiovascular disorders, widespread use of ACE inhibitors as first-line treatments, a surge in generic lisinopril prescriptions, extended use in post-heart attack care, and improving patient adherence to long-term therapies.

Download a free report of the lisinopril market report:
https://www.thebusinessresearchcompany.com/report/lisinopril-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Top Companies Leading the Lisinopril Market
Several prominent pharmaceutical companies dominate the lisinopril landscape, such as Merck & Co. Inc., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zydus Cadila Healthcare Ltd., Hetero Ltd., Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., and Sandoz International GmbH.

Strategic Industry Moves Highlighted by Sun Pharmaceutical Industries
In January 2024, Sun Pharmaceutical Industries Limited, headquartered in India, completed the acquisition of Taro Pharmaceutical Industries Ltd for $347.73 million. This strategic purchase enhances Sun Pharma's portfolio by integrating Taro's strengths in generic and specialty medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Taro, a US-based firm, is a notable supplier of lisinopril, bolstering Sun Pharma's position in the cardiovascular drug market.

View the full lisinopril market report:
https://www.thebusinessresearchcompany.com/report/lisinopril-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Shaping the Lisinopril Market
Innovations in point-of-care testing (POCT) are becoming increasingly important for managing infectious diseases and improving clinical outcomes. Specifically, advancements like microfluidic rapid antimicrobial-susceptibility testing (AST) systems are gaining attention. These systems use tiny fluid channels to quickly culture and analyze bacteria from samples, such as urine, providing antibiotic susceptibility results much faster than traditional methods, which often take several days.

For example, in June 2023, Japan-based diagnostics company Sysmex Corporation unveiled the PA 100 AST System. This compact POCT device employs proprietary microfluidic cartridges under the Sysmex Astrego brand to detect bacteria in roughly 15 minutes and deliver full AST results within about 30 minutes. Its user-friendly design allows healthcare workers to simply insert a patient sample into a disposable cartridge and receive automated results without needing specialized lab training. This rapid diagnostic capability supports quicker antibiotic decisions during the initial patient visit, helping to reduce inappropriate prescribing practices and combat antimicrobial resistance (AMR).

Key Segments in the Global Lisinopril Market Report
The global lisinopril market is systematically categorized into several segments:
1) By Brand: Prinivil, Zestril, Other Brands
2) By Disease: Hypertension, Heart Failure, Heart Attack
3) By Dosage Form: Tablet, Liquid
4) By End-Users: Hospitals, Specialty Clinics

Further breakdowns include:
- Prinivil segment covering different dosage forms and generic variants
- Zestril segment including various dosage forms and generic versions
- Other Brands segment encompassing international brand varieties and combination drug formulations

This segmentation helps to better understand market dynamics and tailor strategies effectively for different product types, therapeutic areas, and consumer bases.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.